المؤلفون: Bousman C., Sundram S., Mostaid M.S., Lee T.T., Chana G., Shannon Weickert C., Pantelis C., Everall I.

مصطلحات الفهرس: single nucleotide polymorphism, smoking, treatment outcome, chlorpromazine, clozapine/pd [Pharmacology], messenger RNA/ec [Endogenous Compound], neu differentiation factor/ec [Endogenous Compound], RNA isoform/ec [Endogenous Compound], protein blood level, adult, aged, article, controlled study, correlational study, disease duration, disease severity, female, genetic variation, human, major clinical study, male, mini international neuropsychiatric interview, onset age, peripheral blood mononuclear cell, Positive and Negative Syndrome Scale, protein expression, quantitative trait locus, schizophrenia/di [Diagnosis], schizophrenia/et [Etiology], Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/38455
Translational Psychiatry
Click here for full text options
LibKey Link

المؤلفون: Bousman C., Sundram S., Mostaid M.S., Lee T.T., Chana G., Shannon Weickert C., Pantelis C., Everall I.

مصطلحات الفهرس: single nucleotide polymorphism, smoking, treatment outcome, chlorpromazine, clozapine/pd [Pharmacology], messenger RNA/ec [Endogenous Compound], neu differentiation factor/ec [Endogenous Compound], RNA isoform/ec [Endogenous Compound], protein blood level, adult, aged, article, controlled study, correlational study, disease duration, disease severity, female, genetic variation, human, major clinical study, male, mini international neuropsychiatric interview, onset age, peripheral blood mononuclear cell, Positive and Negative Syndrome Scale, protein expression, quantitative trait locus, schizophrenia/di [Diagnosis], schizophrenia/et [Etiology], Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/38455
Translational Psychiatry
Click here for full text options
LibKey Link

المؤلفون: Vaddadi K., Waddington J., Clifford J., Hakansson K.

مصطلحات الفهرس: nerve cell membrane, nigroneostriatal system, non insulin dependent diabetes mellitus/si [Side Effect], nonhuman, pathophysiology, plasma, priority journal, psychosis/dt [Drug Therapy], review, schizophrenia, side effect/si [Side Effect], substance abuse, tardive dyskinesia/dt [Drug Therapy], tardive dyskinesia/et [Etiology], tardive dyskinesia/si [Side Effect], weight gain, 4 aminobutyric acid receptor, alpha tocopherol/dt [Drug Therapy], antidepressant agent/ae [Adverse Drug Reaction], antioxidant/dt [Drug Therapy], atypical antipsychotic agent/ae [Adverse Drug Reaction], atypical antipsychotic agent/cm [Drug Comparison], atypical antipsychotic agent/pd [Pharmacology], central stimulant agent/ae [Adverse Drug Reaction], cholinergic receptor blocking agent/ae [Adverse Drug Reaction], clozapine/dt [Drug Therapy], clozapine/pd [Pharmacology], dihomo gamma linolenic acid/dt [Drug Therapy], docosahexaenoic acid/dt [Drug Therapy], dopamine receptor blocking agent, ebselen/dt [Drug Therapy], essential fatty acid/ct [Clinical Trial], essential fatty acid/dt [Drug Therapy], gamma linolenic acid/dt [Drug Therapy], haloperidol, icosapentaenoic acid/dt [Drug Therapy], linoleic acid/dt [Drug Therapy], melatonin/ae [Adverse Drug Reaction], melatonin/dt [Drug Therapy], mood stabilizer/ae [Adverse Drug Reaction], neuroleptic agent/ae [Adverse Drug Reaction], neuroleptic agent/cm [Drug Comparison], neuroleptic agent/pd [Pharmacology], nicotine, omega 3 fatty acid/ct [Clinical Trial], omega 3 fatty acid/dt [Drug Therapy], omega 6 fatty acid/ct [Clinical Trial], omega 6 fatty acid/dt [Drug Therapy], primrose oil/dt [Drug Therapy], prostaglandin/dt [Drug Therapy], psychotropic agent/ae [Adverse Drug Reaction], psychotropic agent/cm [Drug Comparison], psychotropic agent/pd [Pharmacology], quercetin/dt [Drug Therapy], tacrolimus/dt [Drug Therapy], unclassified drug, diphenyldiselenide/dt [Drug Therapy], neurologic disease, absence of side effects/si [Side Effect], aging, balance disorder, cell function, cholinergic system, clinical trial, cognitive defect, diabetes mellitus, disease exacerbation/si [Side Effect], disease predisposition, dopaminergic system, erythrocyte, heredity, human, long term care, nerve cell, Review

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/32167
Click here for full text options
LibKey Link

المؤلفون: Willis G.L., Armstrong S.M.

مصطلحات الفهرس: mental disease/et [Etiology], mesencephalon, nerve cell degeneration, neuroaxonal dystrophy/et [Etiology], neurologic disease/et [Etiology], neuropathology, neurotoxicity/et [Etiology], neurotoxicity/si [Side Effect], nonhuman, Parkinson disease/dt [Drug Therapy], Parkinson disease/et [Etiology], Parkinson disease/su [Surgery], Parkinson disease/th [Therapy], priority journal, review, schizophrenia/et [Etiology], substantia nigra, 1,2,3,6 tetrahydro 1 methyl 4 phenylpyridine, 2 chloro 11 (3 dimethylaminopropylidene)morphanthridine/dt [Drug Therapy], 2 chloro 11 (3 dimethylaminopropylidene)morphanthridine/pd [Pharmacology], alpha tocopherol/pd [Pharmacology], amine/to [Drug Toxicity], antioxidant/pd [Pharmacology], clozapine/dt [Drug Therapy], clozapine/pd [Pharmacology], domperidone/pd [Pharmacology], dopamine, dopamine receptor blocking agent/ae [Adverse Drug Reaction], dopamine receptor blocking agent/cb [Drug Combination], dopamine receptor blocking agent/dt [Drug Therapy], dopamine receptor blocking agent/pd [Pharmacology], dopamine receptor stimulating agent/ae [Adverse Drug Reaction], dopamine receptor stimulating agent/dt [Drug Therapy], dopamine receptor stimulating agent/pd [Pharmacology], flumezapine/dt [Drug Therapy], flumezapine/pd [Pharmacology], fluperlapine/dt [Drug Therapy], fluperlapine/pd [Pharmacology], haloperidol/dt [Drug Therapy], haloperidol/pd [Pharmacology], hormone receptor blocking agent/pd [Pharmacology], levodopa/dt [Drug Therapy], levodopa/pd [Pharmacology], melatonin receptor/pd [Pharmacology], metirosine/pd [Pharmacology], monoamine oxidase inhibitor/pd [Pharmacology], neuroleptic agent/dt [Drug Therapy], neuroleptic agent/pd [Pharmacology], pentiapine maleate/dt [Drug Therapy], pentiapine maleate/pd [Pharmacology], rimcazole/dt [Drug Therapy], rimcazole/pd [Pharmacology], risperidone/pd [Pharmacology], unclassified drug, c 177328, motor dysfunction/si [Side Effect], catecholamine synthesis, akathisia/et [Etiology], brain protection, catecholamine release, diencephalon, dopaminergic system, drug efficacy, drug mechanism, Gilles de la Tourette syndrome/et [Etiology], human, Huntington chorea/et [Etiology], hypothalamus, implant, Lewy body/et [Etiology], Review

URL: Click here for full text options
LibKey Link

المؤلفون: Vaddadi G., Vaddadi K.S., Soosai E.

مصطلحات الفهرس: schizophrenia/dt [Drug Therapy], selenium deficiency/si [Side Effect], trace metal blood level, clozapine/ae [Adverse Drug Reaction], clozapine/do [Drug Dose], clozapine/dt [Drug Therapy], clozapine/pd [Pharmacology], selenium/cr [Drug Concentration], myocarditis/si [Side Effect], adult, agranulocytosis/si [Side Effect], article, blood sampling, cardiomyopathy/si [Side Effect], catecholamine metabolism, dietary intake, female, human, major clinical study, male, oxidative stress, priority journal, risk benefit analysis, schizophrenia/di [Diagnosis], Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/32693
Click here for full text options
LibKey Link

المؤلفون: Pavey G., Copolov D.L., Dean B., Hussain T., Scarr E.

مصطلحات الفهرس: drug effect, drug receptor binding, ligand binding, male, nonhuman, psychosis/dt [Drug Therapy], rat, receptor density, 3 amino 2 (3 carboxypropyl) 6 (4 methoxyphenyl)pyridazinium bromide, 4 aminobutyric acid A receptor/ec [Endogenous Compound], 8 chloro 2,3,4,5 tetrahydro 3 methyl 5 phenyl 1h 3 benzazepin 7 ol hydrogen maleate, chlorpromazine/cm [Drug Comparison], chlorpromazine/do [Drug Dose], chlorpromazine/dt [Drug Therapy], chlorpromazine/po [Oral Drug Administration], chlorpromazine/pd [Pharmacology], clozapine/cm [Drug Comparison], clozapine/do [Drug Dose], clozapine/dt [Drug Therapy], clozapine/po [Oral Drug Administration], clozapine/pd [Pharmacology], dopamine 2 receptor/ec [Endogenous Compound], emonapride, haloperidol/cm [Drug Comparison], haloperidol/do [Drug Dose], haloperidol/po [Oral Drug Administration], haloperidol/pd [Pharmacology], muscimol, olanzapine/pd [Pharmacology], radioligand, tritium, haloperidol/dt [Drug Therapy], olanzapine/po [Oral Drug Administration], neuroleptic agent/cm [Drug Comparison], neuroleptic agent/do [Drug Dose], neuroleptic agent/dt [Drug Therapy], neuroleptic agent/po [Oral Drug Administration], neuroleptic agent/pd [Pharmacology], olanzapine/cm [Drug Comparison], olanzapine/do [Drug Dose], olanzapine/dt [Drug Therapy], animal experiment, animal model, animal tissue, article, brain nerve cell, controlled study, corpus striatum, dose time effect relation, Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/33203
Click here for full text options
LibKey Link

المؤلفون: Vaddadi K., Waddington J., Clifford J., Hakansson K.

مصطلحات الفهرس: nerve cell membrane, nigroneostriatal system, non insulin dependent diabetes mellitus/si [Side Effect], nonhuman, pathophysiology, plasma, priority journal, psychosis/dt [Drug Therapy], review, schizophrenia, side effect/si [Side Effect], substance abuse, tardive dyskinesia/dt [Drug Therapy], tardive dyskinesia/et [Etiology], tardive dyskinesia/si [Side Effect], weight gain, 4 aminobutyric acid receptor, alpha tocopherol/dt [Drug Therapy], antidepressant agent/ae [Adverse Drug Reaction], antioxidant/dt [Drug Therapy], atypical antipsychotic agent/ae [Adverse Drug Reaction], atypical antipsychotic agent/cm [Drug Comparison], atypical antipsychotic agent/pd [Pharmacology], central stimulant agent/ae [Adverse Drug Reaction], cholinergic receptor blocking agent/ae [Adverse Drug Reaction], clozapine/dt [Drug Therapy], clozapine/pd [Pharmacology], dihomo gamma linolenic acid/dt [Drug Therapy], docosahexaenoic acid/dt [Drug Therapy], dopamine receptor blocking agent, ebselen/dt [Drug Therapy], essential fatty acid/ct [Clinical Trial], essential fatty acid/dt [Drug Therapy], gamma linolenic acid/dt [Drug Therapy], haloperidol, icosapentaenoic acid/dt [Drug Therapy], linoleic acid/dt [Drug Therapy], melatonin/ae [Adverse Drug Reaction], melatonin/dt [Drug Therapy], mood stabilizer/ae [Adverse Drug Reaction], neuroleptic agent/ae [Adverse Drug Reaction], neuroleptic agent/cm [Drug Comparison], neuroleptic agent/pd [Pharmacology], nicotine, omega 3 fatty acid/ct [Clinical Trial], omega 3 fatty acid/dt [Drug Therapy], omega 6 fatty acid/ct [Clinical Trial], omega 6 fatty acid/dt [Drug Therapy], primrose oil/dt [Drug Therapy], prostaglandin/dt [Drug Therapy], psychotropic agent/ae [Adverse Drug Reaction], psychotropic agent/cm [Drug Comparison], psychotropic agent/pd [Pharmacology], quercetin/dt [Drug Therapy], tacrolimus/dt [Drug Therapy], unclassified drug, diphenyldiselenide/dt [Drug Therapy], neurologic disease, absence of side effects/si [Side Effect], aging, balance disorder, cell function, cholinergic system, clinical trial, cognitive defect, diabetes mellitus, disease exacerbation/si [Side Effect], disease predisposition, dopaminergic system, erythrocyte, heredity, human, long term care, nerve cell, Review

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/32167
LibKey Link

المؤلفون: Willis G.L., Armstrong S.M.

مصطلحات الفهرس: mental disease/et [Etiology], mesencephalon, nerve cell degeneration, neuroaxonal dystrophy/et [Etiology], neurologic disease/et [Etiology], neuropathology, neurotoxicity/et [Etiology], neurotoxicity/si [Side Effect], nonhuman, Parkinson disease/dt [Drug Therapy], Parkinson disease/et [Etiology], Parkinson disease/su [Surgery], Parkinson disease/th [Therapy], priority journal, review, schizophrenia/et [Etiology], substantia nigra, 1,2,3,6 tetrahydro 1 methyl 4 phenylpyridine, 2 chloro 11 (3 dimethylaminopropylidene)morphanthridine/dt [Drug Therapy], 2 chloro 11 (3 dimethylaminopropylidene)morphanthridine/pd [Pharmacology], alpha tocopherol/pd [Pharmacology], amine/to [Drug Toxicity], antioxidant/pd [Pharmacology], clozapine/dt [Drug Therapy], clozapine/pd [Pharmacology], domperidone/pd [Pharmacology], dopamine, dopamine receptor blocking agent/ae [Adverse Drug Reaction], dopamine receptor blocking agent/cb [Drug Combination], dopamine receptor blocking agent/dt [Drug Therapy], dopamine receptor blocking agent/pd [Pharmacology], dopamine receptor stimulating agent/ae [Adverse Drug Reaction], dopamine receptor stimulating agent/dt [Drug Therapy], dopamine receptor stimulating agent/pd [Pharmacology], flumezapine/dt [Drug Therapy], flumezapine/pd [Pharmacology], fluperlapine/dt [Drug Therapy], fluperlapine/pd [Pharmacology], haloperidol/dt [Drug Therapy], haloperidol/pd [Pharmacology], hormone receptor blocking agent/pd [Pharmacology], levodopa/dt [Drug Therapy], levodopa/pd [Pharmacology], melatonin receptor/pd [Pharmacology], metirosine/pd [Pharmacology], monoamine oxidase inhibitor/pd [Pharmacology], neuroleptic agent/dt [Drug Therapy], neuroleptic agent/pd [Pharmacology], pentiapine maleate/dt [Drug Therapy], pentiapine maleate/pd [Pharmacology], rimcazole/dt [Drug Therapy], rimcazole/pd [Pharmacology], risperidone/pd [Pharmacology], unclassified drug, c 177328, motor dysfunction/si [Side Effect], catecholamine synthesis, akathisia/et [Etiology], brain protection, catecholamine release, diencephalon, dopaminergic system, drug efficacy, drug mechanism, Gilles de la Tourette syndrome/et [Etiology], human, Huntington chorea/et [Etiology], hypothalamus, implant, Lewy body/et [Etiology], Review

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/33759
LibKey Link

المؤلفون: Vaddadi G., Vaddadi K.S., Soosai E.

مصطلحات الفهرس: schizophrenia/dt [Drug Therapy], selenium deficiency/si [Side Effect], trace metal blood level, clozapine/ae [Adverse Drug Reaction], clozapine/do [Drug Dose], clozapine/dt [Drug Therapy], clozapine/pd [Pharmacology], selenium/cr [Drug Concentration], myocarditis/si [Side Effect], adult, agranulocytosis/si [Side Effect], article, blood sampling, cardiomyopathy/si [Side Effect], catecholamine metabolism, dietary intake, female, human, major clinical study, male, oxidative stress, priority journal, risk benefit analysis, schizophrenia/di [Diagnosis], Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/32693
LibKey Link

المؤلفون: Pavey G., Copolov D.L., Dean B., Hussain T., Scarr E.

مصطلحات الفهرس: drug effect, drug receptor binding, ligand binding, male, nonhuman, psychosis/dt [Drug Therapy], rat, receptor density, 3 amino 2 (3 carboxypropyl) 6 (4 methoxyphenyl)pyridazinium bromide, 4 aminobutyric acid A receptor/ec [Endogenous Compound], 8 chloro 2,3,4,5 tetrahydro 3 methyl 5 phenyl 1h 3 benzazepin 7 ol hydrogen maleate, chlorpromazine/cm [Drug Comparison], chlorpromazine/do [Drug Dose], chlorpromazine/dt [Drug Therapy], chlorpromazine/po [Oral Drug Administration], chlorpromazine/pd [Pharmacology], clozapine/cm [Drug Comparison], clozapine/do [Drug Dose], clozapine/dt [Drug Therapy], clozapine/po [Oral Drug Administration], clozapine/pd [Pharmacology], dopamine 2 receptor/ec [Endogenous Compound], emonapride, haloperidol/cm [Drug Comparison], haloperidol/do [Drug Dose], haloperidol/po [Oral Drug Administration], haloperidol/pd [Pharmacology], muscimol, olanzapine/pd [Pharmacology], radioligand, tritium, haloperidol/dt [Drug Therapy], olanzapine/po [Oral Drug Administration], neuroleptic agent/cm [Drug Comparison], neuroleptic agent/do [Drug Dose], neuroleptic agent/dt [Drug Therapy], neuroleptic agent/po [Oral Drug Administration], neuroleptic agent/pd [Pharmacology], olanzapine/cm [Drug Comparison], olanzapine/do [Drug Dose], olanzapine/dt [Drug Therapy], animal experiment, animal model, animal tissue, article, brain nerve cell, controlled study, corpus striatum, dose time effect relation, Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/33203
LibKey Link